Intersect ENT Reports Fourth Quarter and Full Year 2018 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Intersect ENT (XENT) PT Raised to $40 at Canaccord Genuity; Sees Improving Commercial Momentum in 2019
February 26, 2019 7:32 AM ESTCanaccord Genuity analyst Kyle Rose raised the price target on Intersect ENT (NASDAQ: XENT) to $40.00 (from $36.00) while maintaining a Buy rating following results.
"While Intersect clearly lost its "beat-and-raise" luster in 2018, we believe the substantial investment in the commercial and reimbursement... More
Intersect ENT (XENT) Reports In-Line Q4 EPS, Slight Beat on Revenues; Offers Q1 & FY19 Revenue Guidance Below Consensus
February 25, 2019 4:16 PM ESTIntersect ENT (NASDAQ: XENT) reported Q4 EPS of ($0.16), in-line with the analyst estimate of ($0.16). Revenue for the quarter came in at $32.8 million versus the consensus estimate of $32.5 million.
GUIDANCE:
Intersect ENT sees Q1 2019 revenue of $26-26.5 million, versus the consensus... More
